201 Cases of Drug-induced Liver Injury in Children

doi:10.19803/j.1672-8629.2020.10.14

Abstract

Abstract: Objective To investigate the clinical characteristics and patterns of drug-induced liver injury (DILI) in children so as to promote appropriate medication. Methods A total of 201 cases of DILI in children aged 18 or above were collected between January 2013 and December 2017 from the database of Shandong ADR Monitoring Center and analyzed retrospectively. Results Statistical data showed that the incidence of drug-induced liver injury in children aged 13 or above was the highest, accounting for 61.70%. The three dominating types of drugs were anti-infective agents, nervous system drugs, and anti-tumor drugs. The top three drugs that were likely to cause DILI were methotrexate, rifampicin and olanzapine. Most of the cases of DILI occurred within 2 weeks of administration(155 cases, 54.20%), and the median time of DILI occurrence was different between oral administration and intravenous infusion. Most of these patients recovered after discontinuation of drugs and symptomatic treatment. Conclusion Clinicians should learn more about drug-induced liver injury and strengthen the monitoring of anti-infective agents, nervous system drugs, and anti-tumor drugs to ensure the safety of drug use.

Key words: drug-induced liver injury, adverse drug reaction/event(ADR/AE), child, appropriate medication

CLC Number:

R985
R969.3

ZHANG Houli, XU Lili, XIE Yanjun, GENG Tao, SU Fengyun. 201 Cases of Drug-induced Liver Injury in Children[J]. Chinese Journal of Pharmacovigilance, 2020, 17(10): 715-719.

References

[1] Shen T, Liu Y, Shang J, et al.Incidence and Etiology of Drug-Induced Liver Injury in Mainland China[J]. Gastroenterology, 2019,156(8): 2230-2241.
[2] Zeng X, Lu XC, Qin XL,et al.Literature Analysis of Pediatric Drug-induced Liver Injury in China from 2007 to 2016[J]. China Pharmacy(中国药房),2017,28(32):4507-4510.
[3] National Center for ADR Monitoring, China. Technical Specifications and Evaluation Criteria of Common Severe Adverse Drug Reactions (常见严重药品不良反应技术规范及评价标准)[S].2011.
[4] Chen XQ, Jin YY, Tang G. New Pharmacology(新编药物学)[M]. Beijing: People's Medical Publishing House, 2011.
[5] Lucena MI, Andrade RJ, Kaplowiz N, et al.Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex[J]. Hepatology, 2009, 49(6):2001-2009.
[6] Devarbhavi H, Karanth D, Prasanna KS, et al.Drug-induced liver injury with hypersensitivity features has a better outcome: a single-center experience of 39 children and adolescents[J]. Hepatology, 2010, 54(4):1344-1350.
[7] Amin MD, Harpavat S, Leung DH.Drug-induced liver injury in children[J]. Curr Opin Pediatr, 2015, 27(5):625-633.
[8] Hao W, Yu X.Psychiatry(Vol7)(精神病学)[M]. Beijing: People's Medical Publishing House, 2013.
[9] Wang B, Zeng YL,Chen Z, et al.Clinical Features and Nursing Measures of 54 Children with Drug-Induced Liver Injury Caused by Anti-tuberculosis Treatment[J]. Chinese Journal of Liver Diseases(Electronic Version)(中国肝脏病杂志), 2016, 8(2):34-38.
[10] Wang JF, Xiao CW.Clinical Analysis of Liver Damage Related to Antipsychotics[J]. China Practical Medicine(中国实用医药), 2012,7(30):136-137.
[11] Zhang L, Yu WJ, Sheng JH, et al.The Effect of Atypical Antips- ychotics on the Liver[J] Chinese Journal of Clinical Pharmacy(中国临床药学杂志),2014, 23(4):260-264.
[12] Hu LH, Wang XL. Medication Consultation on Application of Aspirin in Children with Kawasaki Disease and Literature Review[J]. Journal of Pediatric Pharmacy(儿科药学杂志),2018, 24(6)33-35.
[13] Zhu XX, Zhu Y, Wang CM.Clinical Features of Drug-Induced Liver Injury in Children[J]. Chinese Journal of Contemporary Pediatrics(中国当代儿科杂志),2012,14(2):131-133.

[1]	SUN Qiyue, ZHAO Ronghua, BAO Lei, GUO Shanshan, GENG Zihan, LI Shuran, XU Yingli, ZHANG Jingsheng, CUI Xiaolan, SUN Jing. Safe doses of Lingyang Ganmao oral liquid for children based on the multi-animal model [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 121-126.
[2]	WANG Xin, SHI Leilei, ZHANG Yuhan, XIE Yundong, LIU Jiping. The role of MRPs transporters in drug-induced liver injury [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 229-234.
[3]	BUCHANAN James. Assessment of drug-induced liver injury via nR modified Hy’s law and P_ALT [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 117-120.
[4]	LIU Wendong, CUI Huanhuan, WANG Xiaohan, SU Xian, WANG Haixue. Status and thinking of Parmacovigilance regulatory system during clinical trials of the pediatric drug in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1002-1006.
[5]	TAI Jun, YU Miao, ZHANG Lin, LEI Yi, LIU Junting, LI Tao, HUANG Guimin, CHENG Yijing, NIE Xiaolu, WANG Qing. Active monitoring of adverse reactions related to haemocoagulase agkistrodon for injection in children [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1011-1016.
[6]	CHEN Chongze, LI Jie, KUANG Lian, TAN Xuewen, LIU Minhui, LIU Xi, ZHENG Yanchai, JIN Hongtao. Characterization of adverse reactions associated with drug-induced liver injury in 448 inpatients [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 697-704.
[7]	. Annual report of national adverse drug reaction monitoring (2022) [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 712-719.
[8]	LI Rongrong, LI Meng, GOU Yue, LUO Qiong, LYU Hua, SUN Xin, LIU Chenghai. Clinical characteristics and risk factors of 113 cases of anti-neoplastic drug-induced liver injury [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 505-510.
[9]	YAO Keyu, ZHANG Shuqi, JIN Rui, LIU Lihong, ZHU Yan. Comparative study on data set of drug-induced liver injury [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 568-573.
[10]	CHEN Chao, ZHU Lan, LIU Lihong, HAN Jiayin, ZHU Yan. Characteristics of Psoralea corylifolia induced liver injury [J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 449-453.
[11]	ZHANG Zhiqi, GUO Mingxing, XU Ye, ZHANG Jian, LIN Jun, CUI Xiangli. One case of tacrolimus-caused reversible posterior leukoencephalopathy syndrome after renal transplantation in children [J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 465-468.
[12]	WANG Yu, HUANG Jingyi, HOU Lixin, LI Shuang, CUI Yongkang, HUANG Lanwei. Humoral immune characteristics of peripheral blood of CAP patients with antibiotic-associated DILI [J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 132-135.
[13]	JIA Zhaoguang, XU Wenshuai, JI Li’na, WANG Linlin, ZHAO Li’na, ZHAO Jingquan, MU Xiangdong. Diagnosis and treatment of mycoplasma pneumoniae pneumonia in children and rational administration of related drugs [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1391-1395.
[14]	PENG Jing, TUO Yali, LI Qiaoling, ZHOU Rong, LI Xinlin, PENG Hui. Data analysis of adverse events of clobazam among children based on foreign pharmacovigilance safety spontaneous reporting system [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1264-1268.
[15]	CHEN Gang, LI Yan, JIANG Caihong, XIE Peitao, SU Changhai. One case of deep coma and severe drug-induced liver injury caused by sulfatinib and oxycodone hydrochloride prolonged-release tablets [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1296-1298.